Undeniable Toxic Ingredients in HPV Vaccines
Let’s shift the lens to the beautiful Pyrenees in Europe where sheep were cherished for their wool, nourishment, and companionship. However, a mysterious sheep illness occurred around a decade ago.
Mysterious post-vaccine sheep illness
In August 2006, an outbreak of bluetongue disease quickly spread to European countries causing a state of emergency.
Bluetongue disease, caused by bluetongue virus (BTV), affects ruminants, mainly sheep, with symptoms of fever, hemorrhages, depression, edemas, and generalized cyanosis, easily observed on the tongue, which explains the disease name.
The campaign seemed to effectively halt viral spreading, however, during the same vaccination period, a series of previously unreported severe diseases emerged in France, Germany, Switzerland, the UK, and Spain, featuring weakness and various neurological symptoms. Veterinarians were stumped, as no known disease explained the tragedy.
Sheep study identifies the problem
Dr. Lluis Lujan, an associate professor of veterinary pathology at the University of Zaragoza in Spain, conducted a sheep study to determine the cause of the unusual diseases.
A total of 21 sheep were assigned into three groups (red, yellow, and green) with seven in each group as follows:
- The red group received commercial sheep vaccines containing aluminum hydroxide.
-
The yellow group received the equivalent dose of aluminum dissolved in water (Alhydrogel®, an aluminum-based adjuvant).
-
The green group was administered a neutral saltwater solution.
The detected level of aluminum found in the lymph nodes in the lumbar spinal cord was much higher in both the aluminum-only (yellow) and the vaccine group (red) compared with the control group, indicating that aluminum created an extra burden needing to be processed by the sheep.
The idea is not only about sheep. We are looking for something that could be happening in humans.
‘Placebo’ trial participant had 40+ symptoms
The Phase 3 clinical trial for Gardasil (FUTURE II study) began in 2002. A particularly large number of participants were recruited in Denmark.
Gardasil clinical trial participant, Sesilje Petersen, developed severe fatigue and a total of 40 symptoms after the second and third shots.
“It was the biggest problem because I was a student at the university and it was very difficult for me to attend the classes as I fell asleep almost daily,” Sesilje said. “I wrote a list with all my symptoms—there were more than 40 symptoms, and some of them had been severe. I had a tumor on my pituitary gland.”
“I received a letter and was invited to this study and it sounded very interesting. So I decided to participate,” recalled Sesilje.
Sesilje kept the information brochure that the participants received at the beginning of the study. It said that the vaccination had already been carefully tested for safety and did not have any serious side effects.
The information about the placebo turned out to be a lie. “It says here that the placebo was saline—the Danish word for saltwater,” she said.
Aluminum: A Toxin in Vaccines for 90 Years
Sesilje’s “saline” placebo contained something highly unusual—aluminum (Al), an adjuvant commonly used in modern vaccines.
She was obviously misinformed about the study design and was unaware of what she was receiving. Prior to participating in the Gardasil study, Sesilje knew that she could not tolerate deodorants containing aluminum.
“We were not informed about the use of aluminum. The word aluminum was not given to us either in the procedure or in their phone consent form.” Sesilje said.
This raises serious ethical concerns about the trial conduct.
Aluminum was first used in human vaccines in 1932 and was the only adjuvant used in licensed vaccines for approximately 70 years. This controversial compound is still used as an adjuvant in vaccines, however, what is its actual role?
Aluminum is the third most abundant metal in the earth’s crust and is widely present in the environment—in plants, soil, water, air, food, and pharmaceuticals. It is present in an ionic form as Al3+.
The absorption of aluminum depends on several factors such as the pH level and the presence of organic acids (citrate, lactate). It is absorbed in a proportion of only 0.1 to 0.3 percent by the gastrointestinal tract in the upper intestine.
Aluminum is a well-known cell killer. It creates harmful molecules called reactive oxygen species, misleads the immune system to become overreactive to our body components, damages the energy supply chain, and is toxic to our DNA.
Christopher Exley, an English professor of bioinorganic chemistry, is one of the most knowledgeable and widely-cited aluminum researchers in the world, with over 200 peer-reviewed scientific papers published on aluminum and over 12,000 citations.
Renal failure patients dialyzed have developed encephalitis linked to excessive brain buildup of aluminum. Those who passed away had a tenfold higher level of aluminum in gray matter, leading to fatal brain diseases in 30 to 50 percent of cases.
Their brain symptoms were correlated with their blood aluminum levels, including issues of speech, coordination, cognition, and fatal seizures.
Dietary absorbed ionic aluminum can leave our body through the kidneys, however, most antigen-aluminum mixtures in vaccines are too large for the kidneys to expel out of our body. Accordingly, vaccine aluminum exposure poses a much higher safety risk than dietary aluminum.
Toxicity Makes Aluminum an Adjuvant
Almost all modern diseases have their origin in a disturbed immune system. No other drug intervenes in the immune system as intensively as vaccines. The role of vaccine components in human immunity is discussed without taboos in the scientific community.
The gold standard to evaluate the effectiveness of a vaccine is based on the antibody level generated. In the beginning, people were not satisfied with a pure inactivated virus to provoke an immune response and wanted to find a substance to help boost immunity and generate a more robust response with longer-sustained antibodies—that is the adjuvant.
Aluminum was found to be a strong adjuvant.
When we inject a vaccine with aluminum into the muscle, we can only imagine what physical and chemical reactions will be triggered. At the very beginning, there may be little response at the injection site.
The only reaction may be due to the damage caused by the needle.
“When the vaccine is injected deeply into the muscle tissue, aluminum ions begin to dissolve and start attacking the surrounding cells,” Mr. Exley stated in the documentary “Under the Skin.”
“So depending upon that rate of dissolution, you will get the degree of cytotoxicity—cell toxicity,” he said.
The aluminum ions kill our normal healthy cells and as those cells die, they release chemical messengers, which call for help from the other immune cells.
Immune cells react immediately and start to attack anything suspicious at the vaccination site. A fierce battle takes place.
As a result, scientists are using aluminum’s toxic effects that can trigger inflammation to begin a battle against an inactive antigen. The toxicity level of aluminum is an alternative term used to describe its ability to produce antibodies in a vaccine.
Manipulated and unethical study
Sesilje’s experience of receiving a placebo containing aluminum instead of saline illustrates how a clinical trial can be designed to manipulate the study results while deceiving study participants.
The published New England Journal of Medicine (NEJM) paper Gardasil FUTURE II clinical trial data clearly states that subjects were receiving either quadrivalent Gardasil or “a visually indistinguishable aluminum-containing placebo.”
Why did the Gardasil clinical trials choose to use aluminum as a comparator instead of saline?
Based on standard pharma clinical research, a normal vaccine study design should use a real placebo (e.g., saline) as a comparative group. Instead, the placebo group in the Gardasil FUTURE II study used a pseudo placebo, which means that it is not a true placebo, but contains a pharmacologically active compound—in this case, it’s aluminum. This is not normal.
“If some of these girls develop the same rare harms, then you can’t see the difference. It’s magic. You mask it, it’s magic. This should not be allowed,” said Dr. Peter Gøtzsche in the documentary “Under the Skin.”
Dr. Gøtzsche is a Danish physician, professor of clinical research design and analysis, and the former leader of the Nordic Cochrane Center in Copenhagen, Denmark.
He is also a co-founder of the Cochrane Collaboration and has published more than 70 papers in the so-called “Big Five” journals: New England Journal of Medicine, The Lancet, Annals of Internal Medicine, British Medical Journal, and Journal of the American Medical Association.
His scientific works have been cited over 30,000 times.
In his paper, “Aluminium-Based Adjuvants Should Not Be Used as Placebos in Clinical Trials,” Mr. Exley stated:
“It is necessary to make a very strong scientific case for using a placebo which is itself known to result in side effects, and I have not found any scientific vindication for such in the recent human vaccination literature.
While severe adverse effects following vaccination are rare, it should not be acceptable to ignore or nullify those effects, which are due to the aluminum-based adjuvant either acting alone or in combination with the antigen.
To do so could place susceptible individuals at risk.”
We see that medical ethics were obviously ignored in the Gardasil trial. Subjects’ health and wellness have been jeopardized without any informed consent.
However, the 2.3 percent of girls and women harmed in the aluminum-treated group is considered unethical and should never have happened.
The true purpose of dosing such an unethical study design appears to have been to hide Gardasil’s ability to harm by keeping it below the manipulated dark background.
This is taken from a long document, read the rest here theepochtimes
Header image: Weerg
Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.